Related Experiment Video

Updated: Apr 11, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

1.4K

Anti-arthritic agents: progress and potential

Sergey S Laev1, Nariman F Salakhutdinov2

  • 1Vorozhtsov Institute of Organic Chemistry, Siberian Division, Russian Academy of Sciences, pr. akademika Lavrent'eva 9, Novosibirsk 630090, Russian Federation.

Bioorganic & Medicinal Chemistry
|May 28, 2015
PubMed

Insights

This review explores anti-arthritis drugs for osteoarthritis and rheumatoid arthritis, discussing current treatments and future agents. More research is needed to find drugs that can prevent disease progression.

Area of Science:

  • Rheumatology
  • Pharmacology

Background:

  • Osteoarthritis and rheumatoid arthritis are common, leading to cartilage breakdown, pain, and joint deformity.
  • Effective anti-arthritis drugs are crucial for managing these debilitating conditions.

Purpose of the Study:

  • To review recent advancements in agents for treating osteoarthritis and rheumatoid arthritis.
  • To discuss the structures, activities, and mechanisms of action of various anti-arthritic agents.

Main Methods:

  • Literature review of existing and developing anti-arthritic agents.
  • Analysis of drug classes including opioids, NSAIDs, DMARDs, natural products, and novel therapeutics.
  • Discussion of potential therapeutic targets for osteoarthritis and rheumatoid arthritis.

Main Results:

  • Various agents are used or in development for arthritis, including opioids, glucocorticoids, NSAIDs, and DMARDs.
  • Natural products, nutraceuticals, and new agents show promise but require further investigation.
  • Current treatments do not prevent disease progression, highlighting a need for novel pharmacologic strategies.

Conclusions:

  • Significant progress has been made in understanding and developing anti-arthritis agents.
  • High-quality trials are essential to validate the efficacy of many studied agents.
  • There is an urgent need for the development of new drugs capable of preventing the progression of osteoarthritis and rheumatoid arthritis.
Keywords:
CyclooxygenaseDisease-modifying anti-rheumatic drugsKinaseMethotrexateNatural productsNon-steroidal anti-inflammatory drugsNutraceuticalsOsteoarthritisRheumatoid arthritis

More Related Videos

Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles05:50

Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles

Published on: June 2, 2023

2.1K
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

1.5K

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
981
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
710
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
2.3K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.5K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
793
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K